DASH SARS-CoV-2 & Flu A/B Test
The FDA-cleared, CLIA-waived DASH SARS-CoV-2 & Flu A/B Test provides qualitative PCR test results in 15 minutes at the point of care allowing you to test and treat with increased confidence in a single patient visit
-
Reduce over- and under-treatment with 15-minute point-of-care PCR testing
-
Improve antimicrobial stewardship and HEDIS compliance
-
Test up to 30 specimens per 8-hour shift*
-
Eliminate empiric treatment with 15-minute point-of-care PCR testing
-
Anterior nasal swab sample collection rather than more invasive nasopharyngeal swabs
-
Self- and clinician-collected specimens
DASH SARS CoV-2 & Flu A/B Test Workflow
1
ADD
2
SCAN
3
LOAD
4
REPORT
Testing and treating in a single patient visit
1
PATIENT ARRIVES
AND SAMPLE IS COLLECTED
2
RUN DASH
SARS-COV-2
& FLU A/B TEST
3
RESULTS
IN JUST
15 MINUTES
4
CLINICIAN PRESENTS
RESULTS AND DISCUSSES
TREATMENT PLAN
Results from a prospective clinical study against an FDA-cleared PCR test
POSITIVE PERCENT AGREEMENT
(Sensitivity)
SARS-CoV-2
95.2%
Flu A
94.3%
Flu B
97.3%
NEGATIVE PERCENT AGREEMENT
(Specificity)
SARS-CoV-2
99.5%
Flu A
98.2%
Flu B
99.2%
Source: DASH SARS-CoV-2 & Flu A/B Test package insert
Intended Use
The DASH SARS-CoV-2 & Flu A/B Test is a rapid reverse transcription polymerase chain reaction (RT-PCR) assay performed on the DASH Rapid PCR Instrument and is intended for the
simultaneous in vitro qualitative detection and differentiation of SARS-CoV-2, influenza A and
influenza B virus ribonucleic acid (RNA) in anterior nasal swab specimens from patients with signs and symptoms of respiratory tract infection. The test is intended to aid in the differential diagnosis of SARS-CoV-2, influenza A, and influenza B in humans in conjunction with other clinical, epidemiologic and laboratory findings.
Positive results of a specific target are indicative of the presence of that viral RNA and may not be the definite cause of disease. Positive results do not rule out co-infection with other pathogens. Negative results do not preclude SARS-CoV-2, influenza A or influenza B infection and should not be used as the sole basis for patient management decisions.